Viking Therapeutics Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics or view top-rated stocks.

Wall Street analysts have given Viking Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Viking Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Viking Therapeutics.

Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, July, 28th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01.
View Viking Therapeutics' earnings history.

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VKTX stock has increased by 27.2% and is now trading at $6.45.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1-year target prices for Viking Therapeutics' shares. Their forecasts range from $13.00 to $21.00. On average, they anticipate Viking Therapeutics' share price to reach $16.00 in the next year. This suggests a possible upside of 148.1% from the stock's current price.
View analysts' price targets for Viking Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Viking Therapeutics include Amarin (AMRN), Revance Therapeutics (RVNC), Xencor (XNCR), ADC Therapeutics (ADCT), Deciphera Pharmaceuticals (DCPH), Trillium Therapeutics (TRIL), IVERIC bio (ISEE), NGM Biopharmaceuticals (NGM), uniQure (QURE), Global Blood Therapeutics (GBT), MorphoSys (MOR), Nuvalent (NUVL), Dynavax Technologies (DVAX), Centessa Pharmaceuticals (CNTA) and Dicerna Pharmaceuticals (DRNA).
View all of VKTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (9.81%), BlackRock Inc. (6.70%), State Street Corp (6.38%), Vanguard Group Inc. (4.20%), Geode Capital Management LLC (1.48%) and Fiera Capital Corp (1.39%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics.

VKTX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Ikarian Capital LLC, Rafferty Asset Management LLC, Citigroup Inc., Invesco Ltd., Bank of America Corp DE, BlackRock Inc., and Victory Capital Management Inc..
View insider buying and selling activity for Viking Therapeutics or view top insider-selling stocks.

VKTX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Goldman Sachs Group Inc., Geode Capital Management LLC, PDT Partners LLC, Bank of Montreal Can, Millennium Management LLC, and Parametric Portfolio Associates LLC.
View insider buying and selling activity for Viking Therapeutics or or view top insider-buying stocks.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VKTX stock can currently be purchased for approximately $6.45.

Viking Therapeutics has a market capitalization of $504.33 million. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

Viking Therapeutics employs 19 workers across the globe.

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Viking Therapeutics is headquartered at 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at (858) 704-4660 or via email at [email protected].